IHC-00196-T
- Brand
- Bethyl Laboratories
- Application
- IHC
- Storage Conditions
- 2 - 8° C
- Host
- Rabbit
- Conjugation
- Unconjugated
- Immunogen
- Between 82 and C-term
- Buffer
- Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide
- Reactivity
- Human
- Target
- p14ARF
- Shelf Life
- 1 year from date of receipt
- Antibody Type
- Polyclonal
- Alternate Names
- alternative reading frame, ARF, CDK4 inhibitor p16-INK4, CDK4I, CDKN2, cell cycle negative regulator beta, CMM2, cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), INK4, INK4A, MLM, MTS1, MTS-1, multiple tumor suppressor 1, P14, P14ARF, P16, P16INK4, p16-INK4, P16INK4A, P16-INK4A, P19, P19ARF, TP16
- Format
- Whole IgG
- Product Type
- Primary Antibodies
- Product Sub Types
- Primary Antibodies
- UNSPSC
- 12352203
- Immunohistochemistry (IHC)
- 1:100 - 1:500
- Target Sentence
- p14ARF regulates the cell cycle by inhibiting mdm2 and stabilizing p53 leading to inactivation of cyclin/CDK complexes. p14ARF is transcribed from an alternate open reading frame (ARF) of the CDKN2A gene. CDKN2A is frequently mutated or deleted in a wide variety of tumors and is known to be an important tumor suppressor gene. The CDKN2A gene also generates a distinct transcript variant and protein p16INK4a.
- Product Link
- http://www.bethyl.com/product/IHC-00196-T